CareDx Stock Surges 28% as Medicare Finalizes Transplant Test Coverage

Key Facts

In a move highlighting the critical impact of regulatory stability on healthcare valuations, CareDx shares experienced a significant surge. The stock jumped 28% following Medicare's finalization of continued insurance coverage for the company's kidney, heart, and lung transplant diagnostic tests. This decision effectively removes a major revenue uncertainty that had been weighing on the company's outlook, providing a clear path for its core diagnostic business.

This regulatory win strengthens CareDx's position relative to molecular diagnostic peers like Natera, which have also faced volatility tied to reimbursement policies. Per market data, the resolution of Medicare coverage is a primary catalyst for biotech valuations, as these tests are integral to the standard of care for transplant recipients. Industry experts note that the finalized coverage significantly de-risks the company's financial profile compared to previous quarters of uncertainty.

CDNA was priced at $29.75 at close on July 15, 2026, after reaching a day high of $29.85. Moving forward, traders should monitor broader market sentiment ahead of the U.S. Monetary Policy Report scheduled for July 10, 2026, which could influence capital flows into the high-growth biotech sector. The stock's ability to maintain these gains will likely depend on its upcoming quarterly performance following this reimbursement clarity.